Clinical trials: Sepsis, Severe
Severe Sepsis
AZD9773 Dose Escalation Study
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773)…
- Trial name
- NCT00615017
- Testing
- AZD9773 (CytoFab)
- Where
- 26 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Sepsis, Hematologic Neoplasms
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for bone marrow transplant (BMT).
- Conditions
- Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
- Trial name
- NCT00067730
- Testing
- Drotrecogin Alfa (activated)
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Severe Sepsis
Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects
The main purpose of this study is to measure the amount of study drug (BMS-986189) in the blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a single dose.
- Trial name
- NCT02739373
- Testing
- BMS-986189
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Bacterial Infections, Bone Diseases, Infectious
Fosfomycin I.v. for Treatment of Severely Infected Patients
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin…
- Conditions
- Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
- Trial name
- FORTRESS (NCT02979951)
- Where
- 50 sites in Austria, Germany and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Sepsis, Shock, Septic
Sepsis Assessment in Belgian Emergency Rooms
To validate the use of the Heparin Binding Protein (HBP) concentration to assist in the evaluation of patients admitting to the emergency department with suspected infection.
- Conditions
- Sepsis, Shock, Septic, Severe Sepsis
- Trial name
- SABER (NCT02424721)
- Where
- 4 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Axis Shield Diagnostics Ltd
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Severe Sepsis, Cardiac Arrest
Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes
A hospitals manual method of patient monitoring will be implemented in an automated system and supported by an early patient deterioration detection for timely escalation.
- Conditions
- Severe Sepsis, Cardiac Arrest, Respiratory Failure
- Trial name
- NCT01692847
- Where
- United Kingdom
- Volunteers
- 678 people
- Sponsor
- Philips Healthcare
Severe Sepsis
An Open Label Study of Severe Sepsis in Adults
This trial is to obtain safety data in adult patients with severe sepsis and two sepsis-induced organ infections who receive an infusion of drotrecogin alfa (activated).
- Trial name
- NCT00568893
- Testing
- drotrecogin alfa (activated)
- Where
- 18 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Severe Sepsis
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
- Trial name
- NCT02960854
- Testing
- Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Sepsis
A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis
The purpose of this study is to determine whether the administration of the study drug is effective in increasing the chance of survival in patients with severe sepsis.
- Trial name
- NCT00034476
- Testing
- sPLA2 Inhibitor
- Where
- 85 sites in United States, Belgium and 3 more
- Volunteers
- 466 people
- Sponsor
- Eli Lilly and Company
Severe Sepsis
Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05060250
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Bluejay Diagnostics, Inc.
Severe Sepsis
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.
- Trial name
- NCT00334828
- Testing
- eritoran tetrasodium
- Where
- 251 sites in United States, Argentina and 22 more
- Volunteers
- 2,000 people
- Sponsor
- Eisai Inc.
Sepsis, Severe Sepsis
Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment
The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a fluid treatment-specific…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03752489
- Testing
- Treatment-specific InSight, InSight
- Volunteers
- 51,645 people, healthy volunteers welcome
- Sponsor
- Dascena
Severe Sepsis
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will…
- Trial name
- NCT00386425
- Testing
- Drotrecogin alfa (activated)
- Where
- 47 sites in United States, Belgium and 7 more
- Volunteers
- 486 people
- Sponsor
- Eli Lilly and Company
Sepsis
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
The purposes of this study are to determine: 1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa…
- Trial name
- NCT00049764
- Testing
- Drotrecogin alfa (activated)
- Where
- 49 sites in United States, Australia and 9 more
- Volunteers
- 474 people
- Sponsor
- Eli Lilly and Company
Acute Kidney Injury
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
- Trial name
- NCT01400893
- Testing
- SCD
- Where
- 26 sites in United States
- Volunteers
- 134 people
- Sponsor
- SeaStar Medical
Severe Sepsis, Septic Shock
GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock
This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.
- Trial name
- NCT01315496
- Testing
- Immunoglobulin G
- Where
- 17 sites in South Korea
- Volunteers
- 214 people
- Sponsor
- Green Cross Corporation
Severe Sepsis, Septic Shock
Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis
The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death.
- Trial name
- NCT01486524
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Sirius Genomics Inc.
Coronary Disease, Heart Valve Diseases
CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)
Over 500,000 patients undergo cardiac surgery with CPB in the United States annually. Although mortality rates have decreased with advances in perioperative care, many patients are affected by postoperative organ dysfunction.
- Trial name
- NCT00107666
- Testing
- CTI-01 (ethyl pyruvate)
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Critical Therapeutics